Late-breaking data show esprit™ btk drug-eluting resorbable scaffold reduces chronic limb-threatening ischemia progression compared to the standard of care

Abbott's new investigational drug-eluting esprit btk (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged artery there is a significant need for more treatments: there are currently no drug-eluting stents, drug-coated balloons or bare-metal stents approved for below the knee (btk) use in the u.s. abbott's landmark life-btk randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that esprit btk offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty san francisco , oct. 25, 2023 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data from the life-btk clinical trial evaluating the esprit™ btk everolimus eluting resorbable scaffold system (esprit btk) in people with chronic limb-threatening ischemia (clti). clti is a severe stage of peripheral artery disease (pad) due to advanced arterial blockage in the lower extremities.
ABT Ratings Summary
ABT Quant Ranking